Preimplantation Genetic Diagnosis Market [2025-2032] - Exclusive Report Featuring In-Depth Analysis and Leading Key Players PerkinElmer, Inc., Genea Limited, Thermo Fisher Scientific Inc.

The Preimplantation Genetic Diagnosis (PGD) market is witnessing significant momentum driven by advancements in genetic screening techniques and rising demand for assisted reproductive technologies. Innovations in next-generation sequencing (NGS) have further enhanced diagnostic accuracy, fueling industry size expansion and repositioning market dynamics. With increasing prevalence of genetic disorders and growing fertility concerns worldwide, PGD is increasingly integrated into fertility clinics to optimize outcomes and reduce inherited disease risks. The Global Preimplantation Genetic Diagnosis Market size is estimated to be valued at USD 61.6 million in 2025 and is expected to reach USD 104.2 million by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Get Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/698

➤ Analyst Opinion

● A strong demand-side indicator propelling PGD market growth is the increasing adoption of personalized fertility treatments. In 2024, more than 40% of fertility clinics in leading regions reported incorporating PGD as a standard preimplantation screening method. This trend contributes directly to rising market share and reinforces the upward market revenue trajectory forecasted for 2025-2032.

● Supply-side innovations have also been pivotal, with major advancements in microarray and NGS platforms enhancing production capacity and lowering costs. For instance, the deployment of novel NGS workflows reduced average PGD testing time by 20% in 2023, improving throughput and access, which is a key enabler for the expanding market size.

● Market analysis reveals a diversification of use cases beyond traditional single-gene disorder detection toward polygenic risk scoring, significantly expanding market scope. Studies in 2025 reported a 30% increase in PGD applications for complex conditions such as cancer predisposition syndromes, highlighting evolving market segments.

● Pricing dynamics remain competitive yet show moderate growth, reflective of the balance between technological sophistication and market penetration. Price adjustments based on region-specific regulatory environments and reimbursement frameworks in 2024 improved affordability, supporting sustained business growth in both emerging and mature markets.

➤ Market Taxonomy and Regional coverage of Report

● Comprehensive Taxonomy of the Report:

» By Technique: Fluorescence In Situ Hybridization (FISH), Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, and Others.
» By Application: Genetic Disorder Screening, Aneuploidy Testing, HLA Typing, and Others.
» By End User: Fertility Clinics, Hospitals, Research Laboratories, and Others.

● Regional and Country Analysis:

» North America: U.S. and Canada
» Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
» Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
» Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
» Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA.

Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/698

➤ Leading Companies of the Market

● PerkinElmer, Inc.
● Genea Limited
● Thermo Fisher Scientific Inc.
● Agilent Technologies, Inc.
● Quest Diagnostics Incorporated
● Illumina, Inc.
● CooperSurgical, Inc.
● Beijing Genomics Institute (BGI)
● LabCorp of America Holdings (Laboratory Corporation of America)
● Natera, Inc.
● Oxford Gene Technology
● California Pacific Medical Center
● Good Start Genetics, Inc.
● Invitae Corporation
● F. Hoffmann-La Roche AG
● Progenesis

Several leading companies have adopted aggressive market growth strategies such as strategic acquisitions and partnerships to enhance their technological portfolios and regional footprint. For example, Illumina, Inc. expanded its market presence by acquiring a regional genetic testing firm in 2024, leading to a 15% increase in its regional market share within one year. Similarly, Thermo Fisher Scientific Inc. introduced a cost-effective NGS platform tailored for emerging markets, driving significant revenue growth and enabling wider accessibility of PGD services globally.

➤Key Growth Drivers Fuelling Market Expansion

Increasing infertility rates coupled with the rising prevalence of genetic diseases have been primary market drivers, resulting in heightened demand for PGD procedures. For example, the WHO reported a 12% global rise in infertility cases in 2023, directly impacting PGD service uptake. Technological advances in genetic screening, especially the integration of AI for data analysis, have improved diagnostic accuracy and reduced turnaround time, boosting market revenue. Rising awareness campaigns about reducing hereditary disorders and improving IVF success rates are expanding market scope in developing nations. Additionally, favorable regulatory frameworks and enhanced reimbursement policies in key regions, such as North America and Europe, have encouraged investments and business growth in the Preimplantation Genetic Diagnosis market.

➤ Key Reasons for Buying the Preimplantation Genetic Diagnosis Report

✦ Comprehensive analysis of the changing competitive landscape
✦ Assists in decision-making processes for the businesses along with detailed strategic planning methodologies
✦ The report offers forecast data and an assessment of the Preimplantation Genetic Diagnosis market
✦ Helps in understanding the key product segments and their estimated growth rate
✦ In-depth analysis of market drivers, restraints, trends, and opportunities
✦ Comprehensive regional analysis of the Preimplantation Genetic Diagnosis market
✦ Extensive profiling of the key stakeholders of the business sphere
✦ Detailed analysis of the factors influencing the growth of the Preimplantation Genetic Diagnosis market

➤ Emerging Trends and Market Shift

The Preimplantation Genetic Diagnosis market is witnessing an increasing shift toward non-invasive PGD techniques, driven by patient preference for safer and quicker diagnostic procedures. Recent clinical trials in 2024 reported a 25% increase in adoption of cell-free DNA analysis, signaling a major trend redefining market growth strategies. Integration of AI and machine learning into genetic data interpretation is optimizing predictive accuracy, generating new market segments and challenging traditional workflows. Furthermore, customized PGD solutions targeting rare genetic disorders catalyze innovation, positioning the market for diversified expansions. Regulatory bodies in Asia Pacific are streamlining approvals for PGD technologies, fostering regional market revenue growth and reshaping industry trends.

➤High-Impact Market Opportunities by Segment and Region

Significant opportunities exist in the Next-Generation Sequencing segment, where demand for high-throughput and high-accuracy platforms is expected to surge due to their expanding application in complex genetic disorder screening. The Fertility Clinics end-user segment offers lucrative growth driven by increasing IVF cycles globally, which reached over 3 million in 2024 according to recent fertility reports. From a regional perspective, Asia Pacific presents a high-impact opportunity supported by rising healthcare infrastructure investments and expanding public awareness campaigns in countries such as India and China. This region recorded a 10.7% market growth rate in 2024, reflecting its strategic importance in the Preimplantation Genetic Diagnosis market landscape.

To Purchase This Premium Report, Click Here (Discount of Up to 25%): https://www.coherentmarketinsights.com/insight/buy-now/698

❓ Frequently Asked Questions

1. Who are the dominant players in the Preimplantation Genetic Diagnosis market?
Leading market companies include PerkinElmer, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., and Genea Limited, which have consistently demonstrated strong market share through innovative technologies and strategic expansions.

2. What will be the size of the Preimplantation Genetic Diagnosis market in the coming years?
The market size is expected to increase from USD 61.6 million in 2025 to USD 104.2 million by 2032, representing a CAGR of 7.8%, driven by technological advancements and rising demand worldwide.

3. Which end user segment has the largest growth opportunity?
Fertility clinics hold the largest growth opportunity due to the rising number of IVF cycles and the increased adoption of advanced genetic screening technologies to improve success rates.

4. How will market development trends evolve over the next five years?
Trends indicate accelerated adoption of non-invasive and AI-driven diagnostic platforms, alongside stronger presence in emerging regions like Asia Pacific, fundamentally shifting industry growth dynamics.

5. What is the nature of the competitive landscape and challenges in the Preimplantation Genetic Diagnosis market?
The competitive landscape is marked by ongoing innovation, aggressive market growth strategies, and regional expansion. Key challenges include regulatory variations and pricing pressures that require adaptive growth strategies.

6. What go-to-market strategies are commonly adopted in the Preimplantation Genetic Diagnosis market?
Market players often leverage strategic partnerships, technology integrations, and localized service models to penetrate new markets and optimize market share, backed by targeted product diversification.

Author of this Marketing PR:

Ravina Pandya, PR Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.

📞 Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
U.S.: + 12524771362
U.K.: + 442039578553
AUS: + 61879247805
INDIA: +91-848-285-0837

About CMI:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

This release was published on openPR.